As the global population ages, pharma is racing to develop therapies that will slow or stop the progression of Alzheimer’s disease. While welcome and necessary, these efforts have saturated the trial environment in developed countries, making treatment-naïve patients more difficult to find and recruit. In response, sponsors are staging a growing number of trials in emerging markets — low- and middle-income countries (LAMIC) such as India and China that are vastly underrepresented in Alzheimer’s disease clinical trial populations.
In a new white paper, Quintiles’ Roza Hayduk, Lynne Hughes and Amir Kalali explore in detail the benefits and challenges of LAMIC-based trials for Alzheimer’s drugs. Experts in neurology and therapeutics, the authors explain why Alzheimer’s studies in emerging markets often draw large groups of participants and motivated clinical investigators, cutting costs in the process. The paper also addresses potential barriers and ways to navigate such hurdles.